The engineered gene, transported via a liposome, will be incorporated and translocated into the nuclei of breast cells. Once the antibodies on the liposome recognize the breast cells, the liposome will be integrated with the targeted cell. Then the engineered gene and the nuclear localization signal, which is attached to the gene, will enter the breast cell. After this delivery into the nucleus of the breast cell, the engineered gene will be transcribed to RNA and translated to protein via cellular machinery. The zinc finger domains, which are attached to the engineered gene, will subsequently target the hypermethylated regions of the BRCA1 and/or BRCA2 genes and the demethylase domain will subsequently remove the excess methyl groups. This biomedical technology will preclude the initiation of uncontrolled cell growth, a hallmark of breast cancer.